Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 44.2% | +38.7% |
| DIAMOND, ALAN D | 1 | 71.8% | +7.8% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.6% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| MCMILLIAN, KARA RENITA | 1 | 30.4% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 34d |
| 18779518 | TREATMENT OF CARDIOPULMONARY DISORDERS | BORI, IBRAHIM D | — |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | — |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1646 | 1 |
| 1621 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18779518 | TREATMENT OF CARDIOPULMONARY DISORDERS | BORI, IBRAHIM D | — | DP | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18182228 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE AND THE PURIFICATION THEREOF FOR USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT | DIAMOND, ALAN D | 3991 | Other | Non-Final OA | 88d overdue | Pending | Mar 10, 2023 |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | PUTTLITZ, KARL J | 1646 | DP | Non-Final OA | — | Pending | Feb 27, 2023 |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | O DELL, DAVID K | 1621 | §103 | Final Rejection | — | Pending | Nov 17, 2022 |
| 17530402 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | MCMILLIAN, KARA RENITA | 1623 | §101Other | Final Rejection | 34d | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial